Equities research analysts predict that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will post earnings per share of ($0.06) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Catalyst Pharmaceuticals’ earnings, with estimates ranging from ($0.07) to ($0.05). Catalyst Pharmaceuticals posted earnings of ($0.05) per share in the same quarter last year, which would indicate a negative year over year growth rate of 20%. The firm is expected to report its next quarterly earnings report on Wednesday, March 21st.

On average, analysts expect that Catalyst Pharmaceuticals will report full year earnings of ($0.22) per share for the current financial year, with EPS estimates ranging from ($0.23) to ($0.20). For the next year, analysts anticipate that the business will post earnings of ($0.28) per share, with EPS estimates ranging from ($0.45) to ($0.13). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Catalyst Pharmaceuticals.

A number of research analysts have issued reports on the company. Piper Jaffray Companies set a $8.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, December 1st. SunTrust Banks reiterated a “buy” rating and issued a $5.00 target price on shares of Catalyst Pharmaceuticals in a research report on Tuesday, September 5th. Roth Capital set a $5.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 1st. Zacks Investment Research cut Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 10th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $6.25.

Hedge funds have recently made changes to their positions in the company. Nationwide Fund Advisors acquired a new stake in shares of Catalyst Pharmaceuticals during the second quarter valued at about $111,000. New York State Common Retirement Fund acquired a new stake in shares of Catalyst Pharmaceuticals during the second quarter valued at about $114,000. State of Wisconsin Investment Board acquired a new stake in shares of Catalyst Pharmaceuticals during the second quarter valued at about $149,000. SG Americas Securities LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the third quarter valued at about $144,000. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Catalyst Pharmaceuticals by 1,861.3% during the second quarter. The Manufacturers Life Insurance Company now owns 63,114 shares of the biopharmaceutical company’s stock valued at $175,000 after purchasing an additional 59,896 shares in the last quarter. 35.57% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals (CPRX) traded down $0.12 during trading on Thursday, reaching $4.01. The company’s stock had a trading volume of 3,566,900 shares, compared to its average volume of 981,389. Catalyst Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $4.51.

COPYRIGHT VIOLATION NOTICE: “Analysts Expect Catalyst Pharmaceuticals Inc (CPRX) to Post -$0.06 EPS” was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/07/analysts-expect-catalyst-pharmaceuticals-inc-cprx-to-post-0-06-eps.html.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.